Non-Small Cell Lung Cancer Clinical Trials

A listing of Non-Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1750 clinical trials
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Resectable, locally advanced NSCLC with involvement of mediastinal lymph nodes (N2) is associated with a high risk of (systemic) recurrence despite neo-adjuvant chemotherapy.

large cell carcinoma
ct scan with contrast
pulmonary function test
adjuvant
renal function
  • 0 views
  • 16 Feb, 2024
  • 13 locations
Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

This study will test the safety of Quad Shot radiation therapy using 2 different treatment schedules to find out what effects, if any, this treatment has on people with advanced NSCLC who are receiving systemic therapy for their cancer. The Quad Shot treatment schedule reduces the number of days needed …

pemetrexed
cisplatin
cisplatin/pemetrexed
dyspnea
systemic therapy
  • 0 views
  • 16 Feb, 2024
  • 7 locations
Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung Cancer

This prospective phase II study is to assess the efficacy and safety of thoracic re-irradiation for locoregionally recurrent non-small cell lung cancer using hypofractionated technique.

  • 0 views
  • 16 Feb, 2024
  • 1 location
Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer

To detect the difference of PD-L1 and miRNA expression profiles of exosomes in NSCLC patients before and after immunotherapy, and to explore the potential of plasma exosomes PD-L1 and miRNAs as biomarkers to predict the therapeutic effect of NSCLC on anti-PD-1 / PD-L1.

  • 0 views
  • 16 Feb, 2024
  • 1 location
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

The primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant treatment versus participants receiving placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed …

non-small cell lung cancer
tislelizumab
pemetrexed
adjuvant
platinum doublet
  • 0 views
  • 16 Feb, 2024
  • 41 locations
A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation

This is a Phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation.

small cell lung cancer
measurable disease
stage iv non-small cell lung cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer

Stage 1 non-small cell lung cancer (NSCLC) carries up to 30% chance of relapse in 5 years. This a phase 2 study that aims to determine the pathological complete response of the combination of stereotactic ablative radiotherapy (SABR) plus nivolumab as neoadjuvant treatment in early-stage non-small cell lung cancer.

prednisone
pulmonary function test
autoimmune disease
neoadjuvant treatment
oophorectomy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Immunotherapy with anti-programmed death 1 (PD-1) antibodies has revolutionized the treatment of metastatic and advanced NSCLC, but its application in neoadjuvant setting has not been well established. Results from a pilot clinical study reported the safety and feasibility of neoadjuvant PD-1 blockade.

proto-oncogene tyrosine-protein kinase ros
pulmonary function test
angiogenesis inhibitor
pd-1 inhibitor
platelet count
  • 0 views
  • 16 Feb, 2024
  • 1 location
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

  • 0 views
  • 16 Feb, 2024
  • 2 locations
Study of Poziotinib in Japanese Patients With NSCLC

A Phase 1/2, open-label, multicenter study to determine dose, tolerability, safety and efficacy of poziotinib in Japanese patients non-small cell lung cancer (NSCLC).

neuropathy
systemic therapy
metastasis
stage iv non-small cell lung cancer
definitive treatment
  • 0 views
  • 05 Aug, 2020